Ozempic 1 (Semaglutide PFS) 1mgx3ml

Semaglutide, the active ingredient in Ozempic 1, works by activating the glucagon-like peptide-1 (GLP-1) receptor. This action enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, thereby helping to regulate blood sugar levels.

The dose of Ozempic 1 is determined by a healthcare provider based on individual patient needs. It is typically started at a lower dose and gradually increased to minimize side effects and achieve optimal glycemic control.

The safety of Ozempic 1 during pregnancy and breastfeeding has not been established. Patients should consult their healthcare provider before using Ozempic 1 if they are pregnant, planning to become pregnant, or breastfeeding.

To order Ozempic 1 from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then reply with pricing, availability, shipping, and the necessary import paperwork.

Ozempic 1 is a once-weekly injection that offers convenient dosing compared to daily oral medications. It is part of the GLP-1 receptor agonist class, which has a different mechanism of action compared to other diabetes medications like metformin or sulfonylureas.

Ozempic 1 should be stored at 2-8°C, kept refrigerated, and protected from light. It should not be frozen or shaken. Always keep the pen cap on when not in use to protect it from light.

Ozempic 1 is administered subcutaneously once weekly. It can be injected in the abdomen, thigh, or upper arm. The injection site can be changed without dose adjustment, and it should not be administered intravenously or intramuscularly.

The most serious risks associated with Ozempic 1 include pancreatitis, hypoglycemia (especially when used with other antidiabetic medications), thyroid tumors (in animal studies), kidney problems, and allergic reactions. Patients should seek immediate medical attention if they experience severe abdominal pain, signs of an allergic reaction, or other concerning symptoms.

Ozempic 1 should not be used by patients with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2). It is also not recommended for patients with a personal or family history of thyroid cancer. Patients should consult their healthcare provider to determine if Ozempic 1 is suitable for them.